BACKGROUND: Chemotherapy, target therapy, and immunotherapy are increasingly being used in the systematic treatment of nasopharyngeal carcinoma (NPC), during which the occurrence of hepatitis B virus (HBV) reactivation might increase. However, data regarding HBV screening and reactivation and the clinical management of NPC patients with HBV infections are lacking. This study was aimed at clarifying the risk of reactivation for NPC patients on different regimens while providing evidence concerning HBV screening and management in an endemic area. METHODS: With the NPC database from an established big-data intelligence platform at Sun Yat-Sen University Cancer Center in China, NPC patients who were diagnosed between 2008 and 2016 and underwent HBV screening and regular monitoring of liver enzymes and HBV deoxyribonucleic acid (DNA) were analyzed. RESULTS: Among the 46,919 patients identified, the HBV screening rate was 24.8% (11,616 of 46,919). Among the screened patients with an HBV infection, regular monitoring of liver enzymes and HBV DNA occurred for 563 patients. The incidence of HBV reactivation and HBV-related hepatitis was 9.1% (51 of 563) and 2.5% (14 of 563), respectively. The reactivation risk varied for different treatments and regimens and ranged from 0.0% to 21.4%. Detectable baseline HBV DNA (odds ratio [OR], 2.93; P < .01), the presence of liver metastasis at diagnosis (OR, 7.19; P < .01), and antiviral prophylaxis (OR, 0.29; P < .01) were significantly associated with reactivation. CONCLUSIONS: In NPC patients with chronic HBV infections on high-risk regimens, the reactivation risk is similar to or exceeds the risk associated with other immunosuppressive therapies for which screening and prophylaxis are recommended. Our findings, therefore, support HBV screening and prophylaxis for these patients, whereas regular monitoring might be appropriate for patients with resolved HBV infections or those receiving low-risk regimens. Cancer 2017;123:3540-9.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with a skewed distribution worldwide both ethnically and geographically. 1 The age-standardized incidence rates range from 20 to 50 per 100,000 males in southern China to 0.5 per 100,000 in white populations. 2 Although the mainstay of treatment has been radiotherapy because of its anatomical location and high radiosensitivity, concurrent chemotherapy with or without induction and/or adjuvant chemotherapy is being increasingly adopted in conjunction with radiation after the success and publication of several important clinical trials. [3] [4] [5] [6] In southern China, where NPC is endemic, the prevalence of chronic hepatitis B virus (HBV) infection is as high as 8% to 15%, whereas 0.3% to 0.5% are infected in the United States. 7 Theoretically, primary HBV infections spontaneously resolve in 95% of adults. In less than 10% of cases, the virus is contracted during the perinatal period, and this can lead to persistent viral replication and chronic HBV infection (these cases are considered hepatitis B surface antigen [HBsAg]-positive).
In addition, low levels of HBV replication in the serum or liver of subjects are considered to indicate resolved HBV infections (HBsAg-negative and hepatitis B core antibody [anti-HBc]-positive). Patients with chronic or resolved HBV infections are prone to complications of HBV reactivation during systematic treatment because of the immunosuppressive effect of the administered chemotherapy. This may result in liver damage, which can disrupt anticancer therapy, compromise a patient's prognosis, and result in severe and fatal hepatic failure. 8, 9 With the increased recognition of the reactivation risk and the availability of effective prophylactic treatments, interest in appropriate HBV screening before chemotherapy initiation has garnered attention. In 2008, the US Centers for Disease Control and Prevention recommended HBV screening before any immunosuppressive therapy, including cytotoxic drugs. 10 In contrast, the American Society of Clinical Oncology in 2010 stated that universal screening for patients receiving chemotherapy for solid tumors was not recommended 11 because there was insufficient evidence of its cost-effectiveness: the prevalence of HBV was low, and the chemotherapy regimens were associated with a low reactivation risk. 12 Being in a geographic region where the incidence of both NPC and HBV infections is high, oncologists are likely to encounter patients suffering from NPC who are infected with HBV. Moreover, the widespread use of cytotoxic chemotherapy, target therapy, and immunotherapy as part of the systematic treatment of NPC may markedly increase the likelihood of HBV reactivation. However, there is a paucity of data regarding HBV screening and reactivation risk and the management of NPC patients receiving radiotherapy and systemic chemotherapy, especially in the era of intensity-modulated radiotherapy (IMRT). Whether there is sufficient evidence for HBV screening and prophylactic antiviral management of these patients remains to be clarified. In this study, we hypothesized that the risk of HBV reactivation would differ with different treatments and cytotoxic regimens. We aimed to clarify the risk of HBV reactivation with different treatments and regimens and to provide evidence for clinical decision making concerning the screening and clinical management of NPC patients with HBV infections.
MATERIALS AND METHODS

Establishment of the Sun Yat-Sen University Cancer Center's Intelligence Platform for Cancer Research
The Intelligence Platform for Cancer Research evolved from the Sun Yat-Sen University Cancer Center in 2015.
It is a novel big-data research system that enables organizing, linking, and structuring real-time data from a number of clinical business systems. It allows health care providers to perform multidimensional big-data queries, attain deep learning, make tacit knowledge explicit, and make the most informed decisions with the greatest opportunities for improving treatment outcomes (Supporting Table 1 [see online supporting information]).
By December 31, 2016, the intelligence platform had aggregated information from 20 core source systems and 8 noncore source systems with more than 200 million data messages, including hospital information systems (eg, admission, discharge, and transfer), electronic medical records, resource information systems, and nuclear, endoscopy, ultrasound, and electrocardiography systems. Furthermore, this system also aggregated data from pathology, laboratory information, radiotherapy, molecular diagnosis, follow-up, anesthesia, bone marrow, and intensive care unit systems. The disease-specific database in this study is one such study included in the Intelligence Platform for Cancer Research. To date, 13 diseasespecific databases, including databases for NPC, lung cancer, gastric cancer, colon cancer, and other cancers, have been generated (Supporting Figs. 1 and 2 [see online supporting information]).
By taking the NPC database as an example (Supporting Fig. 3 [see online supporting information]), we can demonstrate how it processes and accumulates data for NPC automatically on the basis of a well-designed data model and algorithm. Having data on more than 40,000 NPC cases since 2008, the database is continuously growing and being updated. Oncologists can flexibly set query conditions, search for eligible cases, visualize data, and enroll cases into cohort or prospective studies. Data from the research electronic case-report forms can be easily and safely exported into Microsoft Excel for advanced analysis. The current study was based on the NPC database provided by the Intelligence Platform for Cancer Research.
Data Extraction and Study Population
First, we restricted our sample to histologically confirmed NPC patients who received an HBsAg blood test within 6 months of the initiation of treatment by obtaining information from the diagnosis, HBV screening test, and infection screening test variables provided by the big-data platform. Second, we included patients with chronic or resolved HBV infections in the first step. Patients who fulfilled the following inclusion criteria were included in our final analysis: 1) the HBV deoxyribonucleic acid (DNA) status was checked at the baseline, at least every month during treatment, and at least every 4 months for 1 year after the completion of treatment, and 2) liver function was examined before every cycle of chemotherapy. All patients were restaged according to the 7th edition of the International Union Against Cancer/American Joint Committee on Cancer staging system. 13 The study was approved by the Sun Yat-Sen University Cancer Center ethics review board.
Hepatitis Serology and HBV DNA Assay HBV serological markers were detected with commercial enzyme immunoassays. HBV DNA levels were quantified with real-time polymerase chain reaction; the minimum detectable limit was 1000 copies/mL.
Definition of Endpoints: HBV Screening, HBV Reactivation, and Hepatitis
The primary endpoint was the incidence of HBV reactivation, which was defined as a greater than 10-fold increase in comparison with baseline levels or an absolute increase in the HBV DNA level to >10 9 IU mL -1 during treatment and within the first year after the completion of treatment. 9 The secondary endpoints were the HBV screening rate and the incidence of hepatitis. A chronic HBV infection was defined as being positive for HBsAg; a resolved HBV infection was defined as low levels of HBV replication in the serum or liver of subjects who were HBsAgnegative and anti-HBc-positive. Patients who were found to have chronic or resolved HBV were recommended for a consultation with a hepatologist and could be started on prophylactic antiviral therapy at the discretion of the primary oncologist or the hepatologist. Prophylactic antiviral therapy was usually continued up to 6 months after treatment completion.
Hepatitis was defined as a greater than 3-fold increase in serum alanine aminotransferase (ALT) levels that exceeded 100 IU/L.
14 Hepatitis attributable to HBV reactivation was defined as hepatitis with a 10-fold increase in HBV DNA levels in comparison with baseline levels or an absolute increase in the HBV DNA levels to >10 9 IU mL -1 during treatment and within the first year after the completion of treatment in the absence of other systemic infections. Severe hepatitis was defined as a hepatitis flare with an ALT increase exceeding 10 times the upper limit of normal (<58 IU/L). All patients who developed hepatitis because of HBV reactivation were referred to and treated by hepatologists.
Statistical Analysis
Statistical significance was evaluated with the chi-square test (Fisher's exact test or the Pearson chi-squire test as appropriate) for categorical variables and with the MannWhitney U test for numerical variables. To identify characteristics associated with HBV reactivation, we modeled HBV reactivation as an outcome variable with a logistic regression model. The multivariate model with backward elimination included variables that were associated with P .10 and had clinical significance in the univariate analysis. Variables significant at P < .05 in the final multivariate model were considered independent factors. All analyses were performed with STATA 12.0 (Stata Corporation, United States). A 2-sided P value < .05 was considered statistically significant.
RESULTS
HBV Screening Rate
From January 1, 2008 to December 31, 2016, a total of 46,919 newly diagnosed, histologically confirmed NPC patients were enrolled in the Intelligence Platform for Cancer Research. The HBV screening rate was 24.8% (11,616 of 46,919). Among these patients, 3710 (31.9%) were found to be HBsAg-positive, and 2568 (22.1%) were HBsAg-negative and anti-HBc-positive.
Patient Characteristics
Among patients with HBV infections (chronic or resolved infections), the HBV DNA status and liver function were regularly checked for 563 patients. The basic characteristics are summarized in Table 1 . The mean baseline HBV DNA level for the whole cohort was 2.2 3 10 3 IU mL -1
(range, undetectable to 1.2 3 10 9 IU mL -1 ). The mean baseline ALT level for the whole cohort was 29.2 IU/L (range, 4.9-455.2 IU/L). Three hundred ninety-four patients (70.0%) received prophylactic antiviral therapy.
Incidence of HBV Reactivation, Hepatitis, and HBV-Related Hepatitis
In all, 51 patients (9.1%) were identified as experiencing HBV reactivation; 4 patients (7.1%) experienced reactivation more than once. The median time from the start of treatment to HBV reactivation was 13.1 weeks (range, 2.3-278.7 weeks). Among 502 patients with chronic HBV infections, 49 patients (9.8%) experienced reactivation; 2 of the 61 patients with a resolved HBV infection (3.3%) developed the condition. Ten episodes of HBV reactivation occurred during induction chemotherapy, 12 occurred during concurrent chemoradiotherapy, 1 occurred during IMRT alone, 2 occurred during adjuvant chemotherapy, Original Article 13 occurred with palliative treatment, 12 occurred during the follow-up of radical chemoradiotherapy, 1 occurred during the follow-up of IMRT alone, and 4 occurred during the follow-up of palliative treatment (Fig. 1 ). Hepatitis occurred in 66 patients, and 14 of these occurrences (21.2%) were considered to be HBV-related hepatitis flares. Severe hepatitis occurred in 2 patients (3.0%). The median value of the highest ALT levels during hepatitis flares was 127.7 U/L (range, 100.3-989.1 U/ L). The median time from HBV reactivation to the occurrence of hepatitis flares was 4.6 weeks (range, 1-206 weeks). Other possible causes of hepatitis included chemotherapy (28 patients), infection (12 patients), fatty liver (4 patients), tumor progression (5 patients) and herbal medication (3 patients). No HBV-related hepatitis or hepatitis-related deaths occurred ( Table 2) .
Risk of HBV Reactivation According to the Various Types of Treatments and Regimens
We further determined the risk of various types of regimens for the occurrence of HBV reactivation (Table 3) . Gemcitabine and cisplatin (GP), docetaxel, cisplatin, and 5-fluorouracil, and docetaxel and cisplatin were ranked as the top 3 regimens among induction chemotherapies with reactivation rates of 6.3%, 4.2%, and 3.8%, respectively. The reactivation rate of cisplatin-based concurrent chemoradiotherapy was 6.3%, which was lower than the rate of nedaplatin-based concurrent chemoradiotherapy (8.8%) and higher than the rate of docetaxel-based concurrent chemoradiotherapy (4.2%). Notably, 2 patients with radical IMRT alone experienced HBV reactivation during radiotherapy or within 1 year after radiotherapy. 5-Fluorouracil-based adjuvant chemotherapy (tegafur or capecitabine [Xeloda] by mouth) resulted in a 6.9% HBV reactivation rate; no reactivation was observed with other regimens. For patients treated with palliative intent, gemcitabine and capecitabine (GX), GP, and docetaxel and carboplatin (TC) were ranked as the top 3 regimens, with reactivation rates of 12.5%, 8.8%, and 6.3%, respectively.
HBV reactivation was also observed in patients receiving target and immune therapy with or without chemotherapy. The majority of the reactivations (4 of 5) occurred in combination with other chemotherapy regimens; there was 1 strychnine-induced reactivation. The most common target regimens for reactivation involved cetuximab (all in combination with chemotherapy). As for immunotherapy, there was no HBV reactivation attributed to nivolumab monotherapy, whereas 1 reactivation was observed in patients receiving ipilimumab in combination with TC.
Effects of Prophylactic Antiviral Therapy on the Prevention of HBV Reactivation
Twenty-four of the 394 patients who received prophylactic antiviral therapy (6.1%) experienced HBV reactivation, whereas 27 of the 169 patients without prophylactic antiviral therapy (16.0%) developed the condition (P < .01). No significant differences were observed regarding the Abbreviations: 3D-CRT, 3-dimensional conventional radiation therapy; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IMRT, intensity-modulated radiation therapy; NOS, not otherwise specified. a P-values were calculated using the v2 test or independent t-test if indicated.
incidence of hepatitis in the prophylactic antiviral group versus the control group (11.2% vs 13.0%; P 5 .53).
Factors Independently Associated With HBV Reactivation
There were no significant differences in terms of age, sex, baseline Epstein-Barr virus DNA, stage, HBsAg status (P 5 .10), baseline ALT levels, baseline aspartate aminotransferase levels, advanced cancer to the liver, use of corticosteroids, or use of liver-protective drugs between the HBV reactivation group and the nonreactivation group (Table 1) . However, a univariate regression analysis demonstrated that detectable baseline HBV DNA (P 5 .02), the presence of liver metastasis at diagnosis (P 5 .02), and prophylactic antiviral therapy (P < .01) were significantly associated with a higher incidence of HBV reactivation. In a multivariate analysis, factors independently associated with HBV reactivation were detectable baseline HBV DNA (odds ratio [OR], 2.93; 95% confidence interval [CI], 1.37-6.25; P < .01), the presence of liver Table 4 ).
DISCUSSION
HBV reactivation during systematic treatment for cancer is an important health care concern, especially in HBV endemic areas, because the infection rate can be as high as 7% to 8%, 15 and fatal fulminant hepatitis due to HBV reactivation has been reported. 16, 17 However, data on HBV screening and reactivation and the management of patients with NPC are lacking. To the best of our knowledge, this is the first and most comprehensive study investigating the risk of HBV reactivation in NPC patients with chronic and resolved HBV infections from an endemic area. In contrast to other retrospective studies, which have collected data manually, data in this study were stored in and extracted from an established big-data intelligence platform at our cancer center. This enabled the patient population, chemotherapy regimens, and follow-up schedule to be more comprehensive and reliable. Therefore, the characteristic patterns described in this study may help us to better understand the reactivation risk during the systematic treatment of NPC and assist us in designing tailored screening and preventive strategies in the future.
Our data indicated that HBV reactivation induced by systematic treatment for NPC was not uncommon; the overall HBV reactivation risk varied with different treatments and regimens. Generally, the reactivation rate was 9.1%, and it ranged from 0.0% to 21.4% among different regimens. Patients treated with palliative chemotherapy were at the highest risk for reactivation, whereas patients treated with IMRT alone had the lowest risk for reactivation. Cetuximab (in combination with other chemotherapy), GX, nedaplatin-based concurrent chemoradiotherapy, and GP ranked as the top 4 high-risk regimens for HBV by mouth); HBV, hepatitis B virus; IMRT, intensity-modulated radiation therapy; PF, cisplatin and 5-fluorouracil (if another platinum drug such as carboplatin, nedaplatin, or lobaplatin was used, the dose was converted accordingly); TC, docetaxel and carboplatin; TP, docetaxel and cisplatin (if another platinum drug such as carboplatin, nedaplatin, or lobaplatin was used, the dose was converted accordingly); TPF, docetaxel, cisplatin, and 5-fluorouracil (if another platinum drug such as carboplatin, nedaplatin, or lobaplatin was used, the dose was converted accordingly). a Other included tegafur (by mouth), cisplatin, and tegafur (by mouth) plus cisplatin. reactivation. To date, only 2 studies have investigated HBV reactivation in patients with head and neck cancers, 9, 18 and there has been only 1 such study regarding NPC. 17 The reactivation rate ranged from 17.0% to 29.0%. In comparison with those studies, the reactivation rate in our study was lower. The following reasons could explain this discrepancy. First, the sample sizes (all less than 25 patients) were very small in those studies, so the reactivation rate would be more or less exaggerated. Second, the specific regimens for chemotherapy and/or radiotherapy were not clarified, and this could have caused heterogeneity.
Universal screening of patients who receive immunosuppressive treatment is controversial. In 2008, the US Centers for Disease Control and Prevention recommended universal HBV screening for all patients awaiting chemotherapy. 10 However, the American Society of Clinical Oncology recommended screening for patients who were at high risk for HBV infection and for those receiving highly suppressive chemotherapy regimens such as hematopoietic stem cell transplantation and rituximabbased therapy before any forms of chemotherapy.
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According to previously published studies, the reactivation risk ranged from 6% to 10% for patients with HBV infections when they were receiving rituximab-based chemotherapy. [19] [20] [21] Our study demonstrated a higher reactivation rate with some types of high-risk regimens for the treatment of NPC. In addition, the American Gastroenterological Association recently published guidelines on the management of HBV reactivation, 22 and they defined high-risk patients as those with a reactivation risk exceeding 10% or those positive for HBsAg and receiving anthracycline-based chemotherapy. This recommendation, coupled with the high reactivation risk with some regimens, supported routine HBV screening for NPC patients receiving high-risk regimens, such as cetuximab (in combination with other chemotherapy), GX, GP, and nedaplatin-based concurrent chemoradiotherapy. The use of ipilimumab and strychnine was not reported because of the small sample size, even though the reactivation risk exceeded 10%. However, reactivation with those novel agents was documented here, and this is noteworthy. Future studies are needed to help to clarify their exact reactivation risk.
A further concern was the cost-effectiveness of routine HBV screening and prophylaxis for patients on highrisk regimens. In our study, the reactivation rate was 12.5% for GX. The chronic HBV infection rate was 7.9% in our cohort. Consequently, we would expect 35 patients from the 443 unscreened patients who received GX-based chemotherapy to be HBsAg-positive. Of these, 4 patients would experience HBV reactivation. The cost of screening 443 patients is $5.8 3 443, whereas the cost of treating 35 HBsAg-positive patients with prophylactic antiviral therapy during chemotherapy and for an additional 6 months thereafter is $34.9 per week per patient (3 35 3 10 3 4 if we estimate treatment as lasting 10 months), with follow-up blood tests including HBV DNA titers ($16.0 per month per patient) and consultation charges with hepatologists (estimated cost, $14.5 thrice during the whole treatment). In total, we estimate that this could cost $58,535. In comparison, the cost of treating 1 patient who is hospitalized for a median duration of 11 days for acute HBV reactivation is estimated to be $3500 (34, total cost, $14000). 23 Our study thus supports routine HBV screening for NPC patients receiving highrisk chemotherapy followed by prophylactic antiviral therapy.
In this study, several risk factors were independently associated with HBV reactivation in NPC patients, and they could aid in the identification of high-risk patients, predict the occurrence of reactivation, and help in designing tailored preventive strategies. Specifically, prophylactic antiviral therapy significantly reduced the reactivation rate from 16.0% to 6.1% in our study. This was consistent with other studies, which found that reactivation risks ranged from 33% to 67% among those who did not receive prophylaxis and from 0% to 20% among those who received prophylaxis. [24] [25] [26] Interestingly, we also found that liver metastasis at diagnosis was significantly associated with a higher risk of reactivation; this has not been previously reported. Although the mechanism remains unknown and merits future investigation, this finding could assist oncologists in their clinical decision making. Regular monitoring and prophylactic antiviral therapy might be recommended for those patients, whereas regular monitoring alone might be more suitable for low-risk patients.
To date, there are limited studies investigating the reactivation risk in patients with resolved HBV infections and solid tumors. Only 3 studies, all without prophylaxis, have reported the reactivation risk, which ranged from 0.3% to 9% (median, 3.0%). [27] [28] [29] In our study, the reactivation rate was 3.3% for 61 patients with resolved HBV infections. Our study, coupled with other similar findings, suggests that the rate of reactivation of resolved HBV infections is relatively low. Therefore, antiviral prophylaxis is probably not warranted in this circumstance; screening and regular monitoring might be sufficient. The optimal management of these patients still remains to be elucidated, and prospective studies should be conducted in the future. It is also worth noting that the rate of resolved HBV infections among NPC patients was nearly 2568 (5.5%) in our cohort, whereas only 61 patients with resolved HBV (2.4%) underwent routine monitoring of liver enzymes and HBV DNA levels. This indicates that the screening and monitoring of patients with resolved HBV infections merit further attention. The awareness of this important strategy must be addressed, even in groups with low reactivation rates. This cannot be adopted across the board unless oncologists are fully aware of the potential life-threatening consequences of reactivation and hepatitis flares.
Our study is not without limitations. First, in comparing reactivation rates among the different treatments and regimens, we assumed that the HBV infection rate was approximately the same. However, this may not necessarily be so because of the retrospective nature of this study. Prospective studies are needed to further confirm our findings. Second, HBV reactivation might be underestimated because HBV DNA was routinely monitored at 1-month intervals during the treatment and every 6 months for 1 year after the completion of treatment in our study. However, regular HBV DNA monitoring was not widely applied outside the clinical trial setting. In this study, a consistent monitoring algorithm was applied, and the big-data intelligence platform helped us to strictly select qualified patients in a homogeneous way. By doing this, we believe that we have reduced the bias to a large extent.
In conclusion, our study has clarified the risk for patients on different regimens for HBV reactivation, systematically investigated the benefits of HBV screening and antiviral prophylaxis for patients with NPC, and identified the risk factors associated with reactivation. The study provides important knowledge about the risk of HBV reactivation in NPC patients with HBV infections who are receiving systematic treatment, and it places this risk in context across different types of HBV serologies and chemotherapy regimens.
FUNDING SUPPORT
